Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp

IDBI Capital analyst maintained a Buy rating on Tech Mahindra Limited yesterday and set a price target of INR1,922.00. The company’s shares closed ...

IDBI Capital Sticks to Its Buy Rating for Tech Mahindra Limited (TECHM)

ICICI Securities analyst maintained a Buy rating on Tech Mahindra Limited today and set a price target of INR2,000.00. Currently, the analyst conse...

ICICI Securities Sticks to Their Buy Rating for Tech Mahindra Limited (TECHM)

Tech Mahindra Limited ( ($IN:TECHM) ) has shared an announcement. Tech Mahindra has informed the stock exchanges that it has concluded its quarterl...

Tech Mahindra Posts Q3 FY26 Earnings Call Audio, Confirms Compliance with SEBI Norms

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), Bio-T...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Bio-Techne (TECH) and Simulations Plus (SLP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and Bio...

Current Quarter	$0.34	Next Quarter	$0.49
Current Year	$1.67	Next Year	$1.85
QoQ Growth	+44.1%	YoY Growth	+10.8%
3Y EPS CAGR	-35.2%	Target Price	$68.58
Consensus	Buy	Upside	+5.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TECH	$65.25	+1.81%	3.25M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TECH	$65.25	+1.8%	3.25M
3
4
5
6

TECH

TECH

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Bio-Techne Corp Data in Excel

Get Bio-Techne Corp Data in Excel